IRIS
CALCAGNO, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.086
AS - Asia 3.181
NA - Nord America 1.730
AF - Africa 626
SA - Sud America 606
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.242
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 2.334
NL - Olanda 1.875
US - Stati Uniti d'America 1.575
SG - Singapore 1.295
CN - Cina 985
BJ - Benin 473
BR - Brasile 387
VN - Vietnam 337
FR - Francia 331
DE - Germania 131
IN - India 110
MX - Messico 90
HK - Hong Kong 89
GB - Regno Unito 83
AR - Argentina 78
IT - Italia 67
IE - Irlanda 63
BD - Bangladesh 60
ZA - Sudafrica 54
CA - Canada 47
SE - Svezia 46
IQ - Iraq 41
ES - Italia 37
ID - Indonesia 33
PL - Polonia 33
TR - Turchia 32
EC - Ecuador 29
CO - Colombia 28
JP - Giappone 24
SA - Arabia Saudita 24
CL - Cile 23
UA - Ucraina 22
VE - Venezuela 20
KE - Kenya 18
DZ - Algeria 16
PK - Pakistan 16
MA - Marocco 14
PE - Perù 14
PH - Filippine 13
PY - Paraguay 13
AZ - Azerbaigian 11
JO - Giordania 11
EG - Egitto 10
AU - Australia 9
UZ - Uzbekistan 9
KR - Corea 8
PT - Portogallo 8
TN - Tunisia 8
TW - Taiwan 8
KZ - Kazakistan 7
NP - Nepal 7
OM - Oman 7
RS - Serbia 7
SY - Repubblica araba siriana 7
AE - Emirati Arabi Uniti 6
BO - Bolivia 6
ET - Etiopia 6
HU - Ungheria 6
SN - Senegal 6
UY - Uruguay 6
BG - Bulgaria 5
IL - Israele 5
LT - Lituania 5
LV - Lettonia 5
MY - Malesia 5
PS - Palestinian Territory 5
RO - Romania 5
TH - Thailandia 5
XK - ???statistics.table.value.countryCode.XK??? 4
BE - Belgio 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
FI - Finlandia 3
LB - Libano 3
PA - Panama 3
BY - Bielorussia 2
CG - Congo 2
CH - Svizzera 2
CR - Costa Rica 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
GY - Guiana 2
JM - Giamaica 2
KG - Kirghizistan 2
KH - Cambogia 2
LK - Sri Lanka 2
MR - Mauritania 2
MV - Maldive 2
NA - Namibia 2
NG - Nigeria 2
QA - Qatar 2
TG - Togo 2
AO - Angola 1
AT - Austria 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BI - Burundi 1
Totale 11.220
Salva come PNG Salva come JPEG
Città #
Amsterdam 1.871
Singapore 483
Cotonou 473
Ashburn 384
Lauterbourg 316
San Jose 245
Moscow 186
Ho Chi Minh City 117
Beijing 89
Falkenstein 89
Hong Kong 88
New York 86
Los Angeles 78
Hanoi 76
Orem 65
Dublin 59
Tianjin 59
São Paulo 56
Guangzhou 40
Council Bluffs 38
Santa Clara 35
Warsaw 33
Chennai 28
Buffalo 26
Johannesburg 26
Denver 25
Jacksonville 24
Hangzhou 22
Shanghai 22
Atlanta 20
Chicago 20
Mexico City 19
Montreal 19
Poplar 19
St Louis 19
Tokyo 19
Brooklyn 18
Phoenix 18
Rio de Janeiro 18
Houston 17
Stockholm 17
Manchester 16
Nairobi 15
Da Nang 14
Milan 14
New Delhi 13
Quito 13
Shenzhen 13
Querétaro 12
Baku 11
Haiphong 11
Mumbai 11
Toronto 11
Amman 10
Baghdad 10
Asunción 9
Cape Town 9
Jakarta 9
Nuremberg 9
Erbil 8
Frankfurt am Main 8
Lima 8
Riyadh 8
Tashkent 8
Ankara 7
Campinas 7
Chandler 7
Dhaka 7
Guayaquil 7
Hefei 7
Istanbul 7
Lawrence 7
London 7
Princeton 7
Santiago 7
Addis Ababa 6
Belgrade 6
Brasília 6
Dakar 6
Dallas 6
Dammam 6
Durban 6
Goiânia 6
Milwaukee 6
Montevideo 6
San Mateo 6
Suzhou 6
Wilmington 6
Barnet 5
Biên Hòa 5
Boston 5
Dalian 5
Hải Dương 5
Jiaxing 5
Kathmandu 5
La Paz 5
Manaus 5
Medellín 5
Melbourne 5
Minneapolis 5
Totale 5.827
Salva come PNG Salva come JPEG
Nome #
Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease 1.949
Coinfection with other respiratory pathogens in COVID-19 patients 94
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 73
Seroprevalence of SARS-CoV-2 among Workers in Northern Italy 72
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing 71
A Novel HPLC-MS/MS Method for the Intracellular Quantification of the Active Triphosphate Metabolite of Remdesivir: GS-443902 59
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 57
Heart failure in patients with human immunodeficiency virus: a review of the literature 55
A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients 52
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs 52
Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States 52
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1 51
Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study 49
Cardiovascular disease in HIV patients: from bench to bedside and backwards 48
A case of histological diagnosis of Toxoplasma gondii myositis in a person living with HIV 48
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 48
Pharmacogenetics-based Schedule Adjustment of Unboosted Atazanavir-based Regimens: 48 Weeks Results of Reyagen a Randomized and Controlled Pilot Study - PE10/14 47
Incidence and clinical features of stroke in HIV patients in HAART era: a meta-analysis 47
A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era 47
Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial 47
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 45
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 45
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort 45
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 44
A Machine Learning-Derived Cardiovascular Risk Score in People with HIV: The ML-ICONA Score 44
New UPLC-MS/MS method for simultaneous determination of dolutegravir, elvitegravir, rilpivirine and other 14 HIV drugs in human plasma 44
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 43
Assessing ChatGPT's Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and Inclusivity 43
Ageing with HIV: a multidisciplinary review 43
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 42
Pharmacokinetic of caspofungin in patients with invasive candidiasis 42
A noma case report: A warning message from Northern Uganda 42
Alzheimer Dementia in People Living With HIV 41
Knowledge of Sexually Transmitted Infections and HIV among People Living with HIV: Should We Be Concerned? 41
Cerebral white matter Hyperintensities in HIV–positive patients 41
Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders 41
Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotics Supplementation 41
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy 40
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 40
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 40
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects 40
Anti-CD20 antibody therapy for B-cell lymphomas 40
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV) 40
Antiretroviral Drug Penetration into the CNS Compartment 40
Diagnosis of HIV associated Neurocognitive Disorders in Italian cohort: comparison of Clinical Rating and Deficit Score 40
A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment 39
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 39
18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with non-tuberculous mycobacterial infections 39
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 39
A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis 39
Ceftriaxone cerebrospinal fluid levels in adult patients with meningoencephalitis 38
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV 38
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 38
Anti-CD20 antibody therapy for B-cell lymphomas 38
The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? 38
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 38
Staphylococcus aureus meticillino-resistente 38
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 38
Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses? 38
HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era 37
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir 36
Plasma concentration of boosted and unboosted Atazanavir are predicted by 63396C>T SNP in the PXR gene 36
Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma 36
Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases 36
Pharmacogenetics-based Schedule Adjustment of Unboosted Atazanavir Associated with Tenofovir/Emtricitabine: A Randomized Controlled Study (REYAGEN) 36
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 35
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure 35
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 35
Viral rebound after switch to Maraviroc-Raltegravir dual therapy 35
Association between tight junction proteins and cognitive performance in untreated persons with HIV 35
Living with HIV and Getting Vaccinated: A Narrative Review 34
Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study 34
Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants 33
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 33
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine 33
PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations 33
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection 33
Therapeutic Drug Monitoring of Boosted Protease Inhibitors and 48-week Risk of Virological Failure 33
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 33
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients 32
Patterns of Cerebrospinal Fluid Alzheimer’s Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition 32
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4 32
Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted Atazanavir 32
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 32
Dementia, infections and vaccines: 30 years of controversy 32
Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy 32
Disappearance of Renal Stones in an HIV-1-Infected Patient After Reduction of Atazanavir Dose 32
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 32
Pharmacokinetics of maraviroc administered at 150 mg QD in association with lopinavir/ritonavir as a part of a novel NRTI-sparing regimen in naïve patiens 32
Cascade of care for TB infection in persons newly diagnosed with HIV in Italy 31
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens 31
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 31
Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIV 31
Cognitive Rehabilitation Protocol in HIV-AIDS Outpatients with ANI and MND Results and Clinical Applicability 31
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP) 31
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 31
Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare 30
Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen 30
Precision medicine for HIV: where are we? 30
Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation 30
Totale 5.950
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.725
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.725
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 1 6 0
2021/202235 0 0 6 5 1 0 0 0 4 4 7 8
2022/202397 9 7 9 0 4 7 2 3 53 0 3 0
2023/202429 4 3 1 0 5 0 6 0 0 0 2 8
2024/202581 0 0 4 1 0 2 7 11 22 18 3 13
2025/202611.314 8 12 27 1.802 1.807 998 1.585 1.934 2.577 564 0 0
Totale 11.612